TPTX News and Press, Turning Point Therapeutics Inc. From 01/11/21

Present Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Jan. 31 at World Conference on Lung Cancer Provide TRIDENT-1 Study Timeline in First Quarter Provide Clinical Data Interim Updates from Multipl...

Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately $336 Million in Potential Milestone Payments and Royalties ...

The FDA has designated Turning Point Therapeutics' ([[TPTX]] +7.0%) repotrectinib a Breakthrough Therapy status for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer ((NSCLC)) who have not been treated with a ROS1 tyrosine kinase inhibitor.Repotrecti...

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its lead drug candidate, repotrectinib, has been granted breakthrough therap...

Turning Point Therapeutics (TPTX): Q3 GAAP EPS of -$0.42 beats by $0.12.Revenue of $25M beats by $12.5M.Press Release For further details see: Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate , TPX-0022 , Recently Presented Phase 2 TRIDENT-1 Registrational Study Full Site Activation and Timeline Update Anticipated...

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will present a company ov...

Regeneron reports positive data for Dupixent pivotal trial. CytoDyn reports encouraging data for Leronlimab in stroke patients. Turning Point Therapeutics announces positive results from TPX-0022 trial. For further details see: Regeneron's Positive Dupixent Data, And Oth...

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the closing of its previously announced underwritten public offering of 5,28...

Turning Point Therapeutics (TPTX) has priced its public offering of 4,597,702 common shares at $87.00/share, for expected gross proceeds of ~$400M.Underwriters' over-allotment is an additional 689,655 shares.Closing date is October 29.Previously: Turning Point Therapeutics launches equity off...